Drug

Sihuan Pharmaceutical's PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China
HKG: 0460Medical aesthetics

Sihuan Pharmaceutical’s PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China

Sihuan Pharmaceutical (HKG: 0460) announced that two self‑developed, self‑manufactured aesthetics products from its subsidiary Meiyan Space — the Polycaprolactone Microsphere Facial Filler for Injection (PCL) and the Hyaluronic Acid Sodium…

Evopoint Biosciences' XNW26018 Wins NMPA Clinical Trial Approval – Novel Class 1 Macrolide Antibiotic Targets Community‑Acquired Bacterial Pneumonia

Evopoint Biosciences’ XNW26018 Wins NMPA Clinical Trial Approval – Novel Class 1 Macrolide Antibiotic Targets Community‑Acquired Bacterial Pneumonia

Sisram Medical's Profhilo Facial Registration Accepted by NMPA – BDDE‑Free Hyaluronic Acid Biostimulator Poised for China's Aesthetics Market

Sisram Medical’s Profhilo Facial Registration Accepted by NMPA – BDDE‑Free Hyaluronic Acid Biostimulator Poised for China’s Aesthetics Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis
China Medical SystemClinical trial results

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor
Auto-immuneBoao Lecheng pilot zone

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China
Clinical trial approval / initiationHKG: 1093

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

Show More